治疗前18F-FDG PET影像组学分类器预测非小细胞肺癌生存结局的发现与验证
这项七中心研究纳入358例I-III期非小细胞肺癌患者,利用治疗前PET影像提取影像组学特征并建立生存预测分类器。最优特征向量FVX在204例验证集中以中位切点预测14个月生存差异(p=0.00465;HR=1.61,95%CI 1.16-2.24),而在21例TESTI集中未显示生存差异(p=0.501)。结论认为基于常规治疗前影像的PET影像组学分类器具有内在预后信息,可用于风险分层。
要点
- FVX在204例验证集中以中位切点预测14个月生存差异(p=0.00465;HR=1.61,95%CI 1.16-2.24)。
- 在21例TESTI集中FVX未显示生存差异(p=0.501)。
- SUVmax、SUVmean和SUVpeak等临床常规PET变量缺乏预后信息。
核心结论
- 基于常规治疗前PET影像的影像组学分类器具有非小细胞肺癌患者放疗/放化疗风险分层的固有预后信息。
研究设计与样本
- 多中心研究,纳入七家机构2008年10月至2013年12月间采集的358例I-III期非小细胞肺癌患者治疗前PET扫描,患者计划接受放疗/放化疗。
- 采用半自动阈值法分割原发肿瘤,从训练集133例扫描中使用TexLAB v2提取影像组学特征,以LASSO回归进行降维和特征向量发现,多变量分析建立FV、分期与总生存的关系。
- 最优FV在204例独立验证集和21例TESTI集中测试性能。
主要发现
- 358例患者中249例在随访期内死亡,中位随访22个月(范围0-85个月)。
- 从每个原发肿瘤的七个灰度水平各提取665个三维影像组学特征。
- 发现的最优特征向量FVX独立于分期和肿瘤体积等已知预后因素,且不受PET/CT制造商类型影响。
- FVX在204例验证集中以中位切点预测14个月生存差异(p=0.00465;HR=1.61,95%CI 1.16-2.24)。
- 在21例TESTI集(I期癌症生存异常差的小队列)中,FVX正确指示无生存差异(p=0.501)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this multi-center study was to discover and validate radiomics classifiers as image-derived biomarkers for risk stratification of non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Pre-therapy PET scans from a total of 358 Stage I-III NSCLC patients scheduled for radiotherapy/chemo-radiotherapy acquired between October 2008 and December 2013 were included in this seven-institution study. A semi-automatic threshold method was used to segment the primary tumors. Radiomics predictive classifiers were derived from a training set of 133 scans using TexLAB v2. Least absolute shrinkage and selection operator (LASSO) regression analysis was used for data dimension reduction and radiomics feature vector (FV) discovery. Multivariable analysis was performed to establish the relationship between FV, stage and overall survival (OS). Performance of the optimal FV was tested in an independent validation set of 204 patients, and a further independent set of 21 (TESTI) patients. RESULTS: Of 358 patients, 249 died within the follow-up period [median 22 (range 0-85) months]. From each primary tumor, 665 three-dimensional radiomics features from each of seven gray levels were extracted. The most predictive feature vector discovered (FVX) was independent of known prognostic factors, such as stage and tumor volume, and of interest to multi-center studies, invariant to the type of PET/CT manufacturer. Using the median cut-off, FVX predicted a 14-month survival difference in the validation cohort (N = 204, p = 0.00465; HR = 1.61, 95% CI 1.16-2.24). In the TESTI cohort, a smaller cohort that presented with unusually poor survival of stage I cancers, FVX correctly indicated a lack of survival difference (N = 21, p = 0.501). In contrast to the radiomics classifier, clinically routine PET variables including SUVmax, SUVmean and SUVpeak lacked any prognostic information. CONCLUSION: PET-based radiomics classifiers derived from routine pre-treatment imaging possess intrinsic prognostic information for risk stratification of NSCLC patients to radiotherapy/chemo-radiotherapy.
引用
- Arshad MA, Thornton A, Lu H, et al. Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2018. PMID: 30173391. doi:10.1007/s00259-018-4139-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。